Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS

Saad Usmani, MD, MBBS, shares findings from the CANDOR trial, in which the three-drug combination reduced the risk of disease progression or death by 37% compared with the two-drug regimen in patients with relapsed/refractory myeloma.